Study S003262

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VCT220 Tablets in Adults With Type 2 Diabetes Mellitus Inadequately Controlled With Lifestyle Intervention, Metformin Monotherapy, or Metformin in Combination With an SGLT2 Inhibitor

ClinicalTrials.gov record

Registration

Registration: NCT07872436
Acronym: VICTOR-DM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 120
Start: 2026-11-01
Primary completion: 2027-07-01
Lead sponsor: Vincentage Pharma Co., Ltd
Conditions: Type 2 Diabetes Mellitus (DM)
Interventions: DRUG:VCT220 tablets; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change From Baseline in HbA1c [Baseline (Week0) and Week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.